The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE., J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8., 2011 Jan 01

Abstract

This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends.

I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry.

I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

Related Publications

Commentary: It's more than just the price.

Health Serv Res. 2020 Aug;55(4):496-499. doi: 10.1111/1475-6773.13317.
2020 Aug 01

Disparities In outcomes among COVID-19 patients In a large health care system In California.

Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, Brown S, Pressman AR.
Health Aff (Millwood). 101377hlthaff202000598. doi: 10.1377/hlthaff.2020.00598. [Epub ahead of print]
2020 May 21

Insights from a temporal assessment of increases in US private payer coverage of tumor sequencing from 2015 to 2019.

Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA.
Value Health. 23(5):551-558. doi: 10.1016/j.jval.2020.01.018. Epub 2020 Mar 19.
2020 May 01

Assessment of accuracy and usability of a fee estimator for ambulatory care in an integrated health care delivery network.

Stults CD, Li J, Frosch DL, Krishnan H, Smith-McCurdy G, Jones VG, Chan AS.
JAMA Netw Open. 2(12):e1917445. doi: 10.1001/jamanetworkopen.2019.17445.
2019 Dec 02

A clinician's guide to privacy and communication in the ICU.

Francis L, Vorwaller MA, Aboumatar H, Frosch DL, Halamka J, Rozenblum R, Rubin E, Lee BS, Sugarman J, Turner K, Brown SM; Privacy, Access, and Engagement Task Force of the Libretto Consortium of the Gordon and Betty Moore Foundation.
Crit Care Med. [Epub ahead of print]
2016 Dec 02

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Abstract

Pubmed Abstract

Associated Topics

Related Publications

Commentary: It's more than just the price.

Disparities In outcomes among COVID-19 patients In a large health care system In California.

Insights from a temporal assessment of increases in US private payer coverage of tumor sequencing from 2015 to 2019.

Assessment of accuracy and usability of a fee estimator for ambulatory care in an integrated health care delivery network.

A clinician's guide to privacy and communication in the ICU.

About Sutter

Find Care

Featured Services

Patient Resources

Our Team